In breast cancer, the data that cancer-derived factor induced CD204 expression in cultured macrophages rather than CD163 and CD204+ cells predicted poor clinical course rather than CD163 indicated that CD204 might be a marker for protumor phenotype more suitable than CD163 in some organs24. This evidence concerns the gene MSR1 and cancer.